IFNG and colorectal carcinoma: Importantly, increased secretion of IFNG, CXCL9 and CCL23 in the plasma of CRC patients compared to healthy subjects was detected in the validation cohort by Luminex (Figure 4A), suggesting that elevated plasma level of IFNG, CXCL9 and CCL23 might be served as a biomarker of CRC.